Mature myostatin is obtained by proteolytic processing of a biologically-inactive precursor protein, which contains an N-terminal propeptide of 243 amino acid residues. Myostatin-Propeptide exhibits high binding affinity for myostatin, and has been shown to be a potent inhibitor of myostatin. Over-expression of myostatin-propeptide in mice resulted in large increases (up to 200%) in skeletal muscle mass, similar to those observed in myostatin knockout mice. Recombinant Human Myostatin-Propeptide is a 27.8 kDa protein consisting of 244 amino acid residues.
MNENSEQKEN VEKEGLCNAC TWRQNTKSSR IEAIKIQILS KLRLETAPNI SKDVIRQLLP KAPPLRELID QYDVQRDDSS DGSLEDDDYH ATTETIITMP TESDFLMQVD GKPKCCFFKF SSKIQYNKVV KAQLWIYLRP VETPTTVFVQ ILRLIKPMKD GTRYTGIRSL KLDMNPGTGI WQSIDVKTVL QNWLKQPESN LGIEIKALDE NGHDLAVTFP GPGEDGLNPF LEVKVTDTPK RSRR
≥ 98% by SDS-PAGE gel and HPLC analyses.
Determined by its ability to neutralize the Myostatin inhibitory effect of murine MPC-11 cells. The expected ED50 is 0.01–0.04 μg/ml in the presence of 50 ng/ml Myostatin.
Calculated Molecular Weight:
Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug)
Not for human use.